2015
Real world evidence: a form of big data, transforming healthcare data into actionable real time
BARICK, Uttam Kumar; Daniel SCHWARZ; Behsad ZOMORODI; Rituraj MOHANTY; Arun GOWDA et al.Základní údaje
Originální název
Real world evidence: a form of big data, transforming healthcare data into actionable real time
Autoři
BARICK, Uttam Kumar; Daniel SCHWARZ; Behsad ZOMORODI; Rituraj MOHANTY; Arun GOWDA a Martin KOMENDA
Vydání
MEFANET Journal, Brno, Facta Medica, 2015, 1805-9163
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
50300 5.3 Education
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Označené pro přenos do RIV
Ne
Organizační jednotka
Lékařská fakulta
Klíčová slova anglicky
RWE, BIG DIP, big data, data mining, real time insights, business decisions, visual analytics
Změněno: 9. 7. 2016 12:19, RNDr. Martin Komenda, Ph.D., MBA
Anotace
V originále
Data has always played an important role in assisting business decisions and overall improvement of a company’s strategies. The introduction of what has come to be named ‘BIG data’ has changed the industry paradigm altogether for a few domains like media, mobility, retail and social. Data from the real world is also considered as BIG data based on its magnitude, sources and the industry’s capacity to handle the same. Although, the healthcare industry has been using real world data for decades, digitization of health records has demonstrated its value to all the stakeholders with a reaffirmation of interest in it. Over time, companies are looking to adopt new technologies in linking these fragmented data for meaningful and actionable insights to demonstrate their value over competition. It has also been noticed that the consequences of not demonstrating the value of data are sometimes leads regulators and payers to be severe. The real challenge though is not in identifying data sets but transforming these data sets into actionable real time insights and business decisions. Evidence and value development frameworks need to work side by side, harnessing meaningful insights in parallel to product development from early phase to life-cycle management. This should in-turn create evidence and value-based insights for multiple stakeholders across the industry; ultimately supporting the patient as the end user to take informed decisions that impact access to care. This article attempts to review the current state of affairs in the area of BIG data in pharma OR BIG DIP as it is increasingly being referred to.